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Abstract
Studies designed to identify novel methylation events related to cancer often employ cancer cell lines in the discovery
phase of the experiments and have a relatively low rate of discovery of cancer-related methylation events. An
alternative algorithm for discovery of novel methylation in cancer uses primary tumor-derived xenografts instead of cell
lines as the primary source of nucleic acid for evaluation. We evaluated DNA extracted from primary head and neck
squamous cell carcinomas (HNSCC), xenografts grown from these primary tumors in nude mice, HNSCC-derived cell
lines, normal oral mucosal samples, and minimally transformed oral keratinocyte-derived cell lines using Illumina
Infinum Humanmethylation 27 genome-wide methylation microarrays. We found .2,200 statistically significant
methylation differences between cancer cell lines and primary tumors and when comparing normal oral mucosa to
keratinocyte cell lines. We found no statistically significant promoter methylation differences between primary tumor
xenografts and primary tumors. This study demonstrates that tumor-derived xenografts are highly accurate
representations of promoter methylation in primary tumors and that cancer derived cell lines have significant
drawbacks for discovery of promoter methylation alterations in primary tumors. These findings also support use of
primary tumor xenografts for the study of methylation in cancer, drug discovery, and the development of personalized
cancer treatments.
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Introduction
It is well established that alterations in promoter methylation
and the resulting changes in gene expression play a critical role in
the pathogenesis of many human cancers [1]. Hypermethylation
of CpG islands in promoter regions is associated with transcrip-
tional repression of tumor suppressor genes [2,3], while hypo-
methylation is associated with activation of oncogenes [3]. A
common algorithm used for the identification of novel aberrant
methylation events involves applying pharmacologic demethylat-
ing agents, such as 5-aza-29-deoxycytidine (5-aza-dC) to cancer
cell lines, assaying the treated cells for altered gene expression,
and then validating the methylation status of the differentially
expressed genes in primary tumors and normal tissue [4,5,6]. This
algorithm, however, often results in a low yield of cancer-
specific methylation of genes [4,6]. Although cancer cell lines
are attractive for studying methylation in cancer it has been
established that cancer cell line DNA is hypermethylated
compared to primary tissue, and it is suggested that cell lines do
not faithfully represent the methylation status of primary tumors
[7,8,9,10,11], possibly due alterations in methylation that allow
cells to survive in culture [12]. Unlike cancer cell lines, tumor
xenografts are grown in vivo in mice and are not subjected to
frequent high serum environments and frequent passages which
have been implcated in resulting altered methylation [12]. To
date, however, no evaluation has been conducted to compare they
genome-wide methylation profile of tumor xenografts and cancer
cell lines to determine which of these tissues best correspond to
primary tumors. In this study we used head and neck squamous
cell carcinomas (HNSCCs) as a model system to investigate the
methylation profiles of primary tumors, tumor xenografts
(xenografts), normal mucosa, cancer cell lines and normal oral
keratinocyte-derived cell lines using genome-wide methylation
profiling microarrays to determine whether cell lines or tumor




All human HNSCC tissue samples and normal mucosal tissues
were obtained and used according to the policies of the Johns
Hopkins Medical Institutions and Greater Baltimore Medical
Center institutional review boards. Surgical specimens were
obtained from patients who underwent surgery at John Hopkins
HospitalorGreater BaltimoreMedical Center,and the collection of
these tissue specimens was approved by these institutional review
boards. Written informed consent for participation in this study was
obtained from all patients prior to surgery. A small portion of the
tissue removed during the procedure was processed for the study
after routine pathological analysis per the routine standard care for
the patients. After review by a pathologist, a piece of each tumor
specimen was de-identified from the patient and given a unique
identification number and was immediately taken, without freezing,
to be implanted in nude mice for xenograft generation. A separate
piece of the same tumor was microdissected by a pathologist to
assure that greater than 80% of tissue contained HNSCC prior to
being snap frozen in liquid nitrogen. Three primary tumor
specimens are included in this study. Seven normal tissue specimens
were obtained from patients who underwent uvulopalatopharyngo-
plasty (UPPP) for sleep apnea. After review by a pathologist, a
section of dissected mucosal layer from discarded UPPP specimens
was immediately frozen in liquid nitrogen. All specimens were
stored at 280uC until processing.
Xenograft Generation
Our protocol for xenograft implantation was approved and
carried out in strict adherence to the policies and guidelines set
forth by The Johns Hopkins University Animal Care and Use
Committee (Protocol #: MO08M248). All surgery was performed
under isoflurane-induced anesthesia and every effort was made to
minimize suffering. Briefly, fresh tissue from 3 primary HNSCCs
was implanted in the flank of nude mice at the Johns Hopkins
Hospital. Prior to implantation the xenograft area was sterilized
using iodine solution. Two small 2 mm incisions were made on
each side of the flanks using sterile scissors, and tumor tissue
measuring 2 mm62 mm and treated with Matrigel were implant-
ed under the skin. Tumors were allowed to grow until tumor
volume equaled 20 mm620 mm. Animals were then euthanized
by carbon dioxide asphyxiation followed by cervical dislocation, as
approved by the AVMA panel on Euthanasia, and the xenografts
were harvested.
Cell Lines and Culturing Conditions
JHU-O11 and JHU-O22 cell lines were created from primary
HNSCCs in the Division of Head and Neck Cancer Research, the
Johns Hopkins University (Baltimore, MD).[13] UM22A and
UM22B cell lines were provided by Ajay Verma (Merck & Co.,
North Wales, PA) and FaDu cells were obtained from the
American Type Culture Collection. OKF6 cells are a mini-
mally transformed oral keratinocyte line donated by Dr. James
Rheinwald (Department of Dermatology, Brigham and Women’s
Hospital and Harvard Skin Disease Research Center). NOK-SI
cells are normal oral keratinocytes that spontaneously immortal-
ized and were provided by Dr. Silvio Gutkind (National Institutes
of Health, Bethesda, MD).
JHU-O11, JHU-O22 and FaDu cell lines were cultured in
RPMI-1640 media supplemented with 10% FBS and 1%
penicillin-streptomycin. UM22A and UM22B cell lines were
cultured in high-glucose DMEM with 10% FBS and 1%
penicillin-streptomycin. OKF6 cell lines were grown in keratino-
cyte serum-free medium supplemented with bovine pituitary
extract (25 mg/ml), calcium chloride (0.4 mM), epidermal growth
factor (0.2 ng/ml) and 1% penicillin-streptomycin that was filtered
through 0.2-mm pore-size sterilization filter prior to use. NOK-SI
cells were grown in fully supplemented keratinocyte serum-free
medium. All media components were obtained from Gibco
Invitrogen Corporation (Carlsbad, CA). Cell growth conditions
were maintained at 37uC in an atmosphere of 5% carbon dioxide
and 95% relative humidity.
DNA extraction
DNA was extracted from all samples by digestion with 50
mg/mL proteinase K (Boehringer, Mannheim, Germany) in the
presence of 1% SDS at 48uC overnight, followed by phenol/
chloroform extraction and ethanol precipitation.
Bisulfite conversion for microarrays
Bisulfite conversion of genomic DNA was done with the EZ
DNA methylation Kit (Zymo Research, D5002) by following
manufacturer’s protocol with modifications for Illumina Infinium
Methylation Assay in the Johns Hopkins microarray core.
Microarray analysis
Bisulfite-converted genomic DNA was analyzed using Illumina’s
Infinium Human Methylation27 Beadchip Kit (WG-311-1202) in
the Johns Hopkins microarray core. Beadchip contains 27,578
CpG loci covering more than 14,000 human RefSeq genes at
single-nucleotide resolution. Chip process and data analysis were
performed by using reagents provided in the kit and following
manufacturer’s manual. Data were extracted and summarized
using BeadStudio v3.0 software. Arrays that did not pass quality
control in terms of b-distributions and expected p-values across the
arrays were removed from further analysis. All microarray data
are MIAME compliant and have been submitted to the Gene
Expression Omnibus (GEO Accession ID: GSE24787).
Comparison between specimen groups
Data were preprocessed using a custom R script to retain only
methylation probes containing $3 CpG sites per probe. These
probes were chosen based on our prior experience that probes that
included $3 CpG sites per probe demonstrated consistently
reproducible methylation status by bisulfite sequencing, providing
a higher quality read. There were 12,023 probes retained for 3
tumors, 3 xenografts, 7 UPPPs, 5 cancer cell lines, and 2 normal
mucosa-derived cell lines. Empirical Bayes comparisons were
made between different tissues and cell lines using the limma
package [14] in R/Bioconductor [15] to determine the difference
in methylation between these groups.
Unsupervised hierarchical clustering
Normalized data for the percentage methylated CpG sites for
all high quality probes on the Illumina array were subjected
to unsupervised hierarchical clustering analysis with Euclidean
distance and average linkage using the MultiExperiment Viewer
(MeV) application [16].
Bisulfite conversion for sequencing
Bisulfite conversion of 2 ug genomic DNA from all samples was
conducted using the Qiagen EpiTect bisulfite conversion kit per
the manufacturers protocol. (Qiagen, Valencia, CA).
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Bisulfite sequencing was conducted for the 3 CpG sites probed
in the promoter regions of TM4SF19 (NCBI Accession #:
NM_[13]8461.1; Chromosome 3:196,015,593–196,115,592 Illu-
minia probe ID: cg05445326;) and SERPINA12 (NCBI Accession
#: NM_173850.2; Chromosome 14: 94,933,839–95,033,838;
Illumina probe ID: cg05485062) (Table 1) as well as for four
other probes on the array (Table S1). Probes to be included were
chosen from a list of genes with significant differential methylation
between tumor-xenografts and cell lines (Table S2). Probe location
on the human genome was determined using the NCBI Basic
Local Alignment Search Tool and the UCSC Genome Browser
utilizing the March 2006 human reference assembly (NCBI Build
36.1). Bisulfite-treated DNA was amplified using primers designed
using MethPrimer [17] to span the sequence of the probes used on
the Illumina Humanmethylation27 array. Array sequence data
were obtained from the ‘‘Illumina Human Methylation Sequence
Data.csv’’ file available for download at www.illumina.com.
Primer extension sequencing was performed by GENEWIZ, Inc
(South Plainfield, NJ) using Applied Biosystems BigDye version
3.1. The reactions were then run on Applied Biosystem’s 3730xl
DNA Analyzer.
Comparison of methylation array and bisulfite
sequencing results
Methylation array data and bisulfite sequencing results were
compared using the Freeman-Halton extension of the Fisher exact
probability test for a three-rows by three-columns contingency
table comparing methylation status. Bisulfite sequencing were read
as fully methylated, partially methylated, and methylated based on
analysis of sequencing tracings. If there was only a peak for a ‘‘C’’
or a ‘‘T’’ at the CpG site being analyzed the CpG site was called
either methylated or unmethylated, respectively. If a peak had a
mixed signal with both ‘‘C’’ and ‘‘T’’ peaks, the CpG site was
deemed to be hemimethylated if the smaller peak was at least
20%–80% of the height of the larger peak. If the smaller peak was
,20% the height of the larger peak the CpG site was called as
either methylated or unmethylated based on the dominant peak.
Illumlumina array data was read as fully methylated for b.0.75,
hemimethylated for 0.25,b,0.75, and unmethylated for b,0.25.
All p-values were corrected by the Bonferroni method for multiple
testing.
Gene Set Analysis
Gene set analysis (GSA) was performed comparing all tissue
groupings. Results were sorted by t-statistic and a Wilcoxon rank
sum test performed on sets of genes defined by the Broad
Institute. The set used was the Gene Ontology Biological
Process c5.bp.v2.5. This permitted GSA to be performed on all
methylation probes passing the quality control. Resulting p-values
from the Wilcoxon rank sum test were corrected with Benjamini-
Hochberg multiple testing correction. An alpha value of 0.05 on
the corrected p-value was used for significance.
Results
Preliminary analysis was conducted using the 12,023 probes on
the arrays that included $3 CpG islands per probe using empirical
Bayes comparisons for all tissue types. This analysis revealed
.2200 differentially methylation probes when comparing primary
tissue (tumors or normal mucosa) to cell lines. There were 412
probes with significant differential methylation when comparing
minimally transformed keratinocyte cell lines to HNSCC-derived
cell lines, and 98 probes with a statistically significant difference in
methylation between primary tumors and UPPPs. There were no
statistically significant differences in methylation between tumors
and primary tumor xenografts. (Table 2 and Tables S1, S2, S3,
S4, and S5).
The individual statistically significantly differentially methylated
probes from each comparison were then plotted on a Venn
Table 1. Bisulfite sequencing primers use for validation of differentially methylated targets identified with the Illumina
Humanmethylation27 microarrays.
Gene Name Gene ID Illumina Array ID Forward Primer Reverse Primer
ZFN671 NM_024833 cg19246110 TTTTGTGTTGATGAGAATTTTGTTT TACATACCCAATAAAAACCCAAAAA
TRIM58 NM_015431 cg07533148 ATAGTTTTTGTTTTAGGTGTATTTT ATAAACTAAACCACACAACCCTCC
MAGEA3 NM_005362 cg07545232 TGAGGTTTTTTGTTTGAGGTGA CATCAACTTCAAAACCCTAAAAAATA
TM4SF19 NM_138461 cg05445326 TAGGATTTTTTTTAGGAGGGTTAGG TAATACAAAAACCATACAACACATC
SERPINA12 NM_173850 cg05485062 GTAGGGAGTATAGTGGAGGGTTTTAA AAATACAAACATCCCCAAATATCAA
IRF8 NM_002163 cg24826867 TTTTGGATTTTAGGTGTGAGGAG TACCAATCTTTAAAAACAAACAAAC
*Gene name, NCBI Gene ID, Illumina Humanmethylation27 Array Probe ID and primer sequences are provided.
doi:10.1371/journal.pone.0020584.t001
Table 2. Analysis of the 12,023 probes with $3 CpG sites/
probe.
Comparison
Number of Genes with
Significantly Different
Methylation
Normal Tissue vs Cancer Cell Lines 2734
Normal Tissue vs Minimally
Transformed Cell Lines
2727
Primary Tumors vs Cancer Cell Lines 2211
Minimally Transformed Cell
Lines vs Cancer Cell Lines
412
Primary Tumor vs Normal Tissue 98
Primary Tumor vs Tumor-Derived Xenograft 0
*Analysis of the 12,023 genes with $3 CpG sites/probe. All samples were
compared in a pairwise fashion. For all primary tissue compared to cell lines
there were .2200 genes with a statistically significant methylation differences
as determined by having a Benjamini-Hochberg adjusted p-value,0.05. When
primary tumor was compared to normal tissue, 98 genes had a statistically
significant difference in methylation. There were no statistically significant
differences in methylation between tumors and tumor-derived xenografts.
doi:10.1371/journal.pone.0020584.t002
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probes for all comparisons (Figure 1). There was a high degree of
overlap between the genes that were differentially methylated in
the tumor vs. cancer cell line comparison and the normal mucosa
vs. cancer cell line comparison with 82% and 62% of the
genes appearing in each group, respectively. Gene set analysis
demonstrated differences in genes involved in cell cycle progres-
sion and cell growth (Table S6).
The data from all 12,023 high quality probes ($3 CpG islands)
for each sample were then subjected to unsupervised hierarchical
clustering analysis (Figure 2). After the first branch point on the
dendrogram, 5 of the 6 cell lines segregated from all of the primary
tissue specimens and one of the normal oral mucosa-derived cell
lines (OKF-6). At the second branch point all of the tissues
segregated from the OKF6 cells. At the terminal branches of the
dendrogram all of the primary tumors segregated with their
corresponding xenografts and all of the UPPPs segregated
together. This demonstrates that methylation differences segre-
gated primarily according to whether or not cell grew in adherent
cell culture conditions, and that primary tumor xenografts most
closely resemble primary tumors in promoter methylation
patterns.
Bisulfite sequencing of the specific CpG sites probed by the
Illumina arrays was conducted to validate the data obtained from
the methylation microarrays. Sequencing data were obtained for
six genes with high statistically significant differential methylation
between tumors and cell lines for all specimens (Figure 3 and
Table S7). The results of the methylation arrays and the bisulfite
sequencing tests were compared using 363 contingency tables and
the generalized Fisher test. The methylation arrays were ranked
as unmethylated (beta,0.25), partially methylated (0.25,beta
,0.75), and methylated (beta,0.75). All comparisons were




This is the first study to directly compare the whole-genome
locus specific promoter methylation profiles of primary HNSCC,
HNSCC tumor xenografts, and HNSCC cell lines. Although we
had a relatively small sample size, our findings are consistent with
several previous studies have compared methylation levels in
tumors and cell lines from multiple different tissue types and have
Figure 1. Venn Diagram of Methylation Differences Between
Groups. There is a high degree of overlap between the probes
differentially methylated in primary tumors vs. cancer cell lines, and in
normal mucosa vs. cancer cell lines.
doi:10.1371/journal.pone.0020584.g001
Figure 2. Unsupervised hierarchical clustering of methylation
array data. All cell lines segregate from primary tissue by the second
branch point of the dendrogram. All tumor/xenografts pairs cluster
separately from the normal mucosa specimens by the fourth branch
point of the dendrogram. Primary tumors and their corresponding
xenografts cluster together after the terminal branch points.
doi:10.1371/journal.pone.0020584.g002
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when compared to primary tumors. [7,10,18,19], including one
study that compared tumor, xenograft, cell line and normal tissue
whole-genome methylation profiles [20]. One recent study by
Houshdaran and colleagues compared methylation profiles of
ovarian epithelial cell carcinomas and cell lines at 1,505 GpG sites,
representing 808 genes [21]. This study demonstrated a distinct
difference in methhylation profiles of tumors and cell lines. 8% of
the genes that we found to be differentially methylated in our study
were also found to be differentially methylated in the smilar
comparison made by Houshadaran and colleagues with ovarian
cancers and ovarian cancer cell lines (Table S8). Another recent
study by Milne and colleagues compared methylation profiles of a
gastric cancer specimen, a xenograft from that cancer and 2 gastric
cancer cell lines [22]. Similarly to our study, Milne and colleagues
found that the methylation pattern in cell lines is different from
primary tissues. This study, however, only looked at 38 genes. Paz
and colleagues compared methylation of 15 genes in primary
tumors and cell lines for 12 different tumor types, including
HNSCC, and found that the methylation profile for these 15 genes
is similar in primary tumors and corresponding cell lines [19]. This
study, however, looked at methylation only for a subset of genes
and did not evaluate the whole-genome promoter methylation
profile. Of the 15 genes evaluated by Paz and colleagues, only DCC
is seen in common with the 98 genes differentially methylated
between normal tissue and primary tumors (Table S5, [19]).
The high degree of similarity between primary tumors and
xenografts derived from those tumors, and the substantial
discordance in methylation between primary tumors and cancer
cell lines demonstrates that xenografts are more accurate models
for promoter methylation in cancer than cancer cell lines.
Although it is expected that the methylation of each individual
xenograft would be similar to its corresponding primary tumor, all
of the tumor-xenograft pairs had overall similar methylation
patters as seen on hierarchical clustering while all of the cell lines
had similar methylation patterns (Figure 2). It is possible that the
different origin of the tumor samples and the cell line samples
could explain some of the difference in their overall pattern of
Figure 3. Representative bisulfite sequencing results for validation of microarray data. Bisulfite sequencing of the CpG sites probed by
the array shows a high degree of concordance with the methylation array results. The methylation status of each CpG site is shown by bisulfite
sequencing. Array intensity is an aggregate of the methylation status of the 3 CpG sites interrogated by each probe. All comparisons were significant
after Bonferroni correction with a maximum corrected p-value of 2610
25. Each CpG interrogated by bisulfite sequencing is included in the figure.
Array signal is a summation of the methylation status of the CpG’s being interrogated. (Black box=Full Methylation; Grey Box=Hemi-methylation;
White box=Hypomethylation).
doi:10.1371/journal.pone.0020584.g003
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of similarity between the methylation pattern seen in the cancer
cell lines, regardless of tissue of origin. A more likely explanation is
that cell line methylation is affected by the tissue culture
environment, which is not present in first generation xenografts.
An important implication of our finding that xenografts have
identical methylation to the primary tumor from which they were
derived, is that researchers can use xenografts as a primary tissue
source for studying methylation in cancer. By growing xenografts,
the quantity of primary tissue available for study can be greatly
expanded, allowing for more experiments to be conducted on each
sample without a loss in the fidelity of the methylation status of the
xenografts. Additionally, although discovery of promoter methyl-
ation alterations in cancer has classically been done using cell lines
[4,5,6], it is possible to conduct demethylation in vivo in nude
mice carrying tumor xenografts, by exposing the mice to systemic
5-aza-dC [23]. Treating xenograft-carrying mice with a demethy-
lating agent and then screening the xenografts for altered gene
expression would provide a more cancer specific discovery
approach which could potentially increase the yield of novel and
truly cancer-related aberrantly methylated genes identified by the
screen. Although our results indicate that cell line methylation is
not representative of primary tumors, cell lines are still useful for
demonstrating the biological effects of hyper- and hypomethyla-
tion. Cell lines still provide a useful platform for conducting
functional experiments on genes affected by altered methylation in
cancer, such as gene knock-down or gene over-expression to
validate the biological significance of aberrant methylation events
in cancer. However, these data indicate that cancer cell lines are a
poor representation of promoter methylation events in primary
tumors, and that substantial artifact related to epigenetic
alterations and promoter methylation exists as an artifact of
adherent cell culture.
In addition to promoter methylation discovery, our findings also
have implications for drug discovery in all human cancers. With
the emergence of whole-genome SNP, genome-wide methylation,
and gene expression microarrays, among other platforms, it has
become possible to conduct integrative pathway analysis in any
human cancer to identify the core key pathways involved in cancer
development and progression [24]. Tumor xenografts are an
attractive model for testing novel therapies targeting components
of nodes of interest in core pathways. A number of previous
studies have demonstrated that tumor xenografts grown in
immune compromised mice may be useful in drug development
[25,26,27,28]. It has also been suggested that xenografts could
have a role in personalized medicine by allowing for the in vivo
testing of chemoresponsiveness of a patient’s tumor [29,30]. One
limitation to using xenografts in personalized medicine is the low
engraftment rate of primary tumors in mice, however, a recent
study has shown that tumor-derived non-small cell lung cancer
(NSCLC) implanted under the renal capsule of NOD-SCID
mice have a 90% engraftment rate and grow rapidly enough to
potentially be useful for aiding in the direction of a patient’s
chemotherapeutic regimen [31]. It has been previously shown that
tumor xenografts have global gene expression profiles that are very
similar to the primary tumors from which they were derived [32].
Our results demonstrate that tumor xenografts have methylation
signatures that are identical to the primary tumors.
These data demonstrate that xenografts have a global methy-
lation pattern that is highly representative of the primary tumor
from which they are derived and that tumor-derived cell lines have
a distinctly different methylation signature than both primary
tumors and tumor xenografts. Although we did not investigate
methylation difference between primary tumors, xenografts and
cell lines in other solid tumors it is likely that the differences seen
here, which we believe are attributable to cells being grown in
culture, will also be seen in cancer cell lines derived from other
human solid tumors.
Supporting Information
Table S1 Minimally transformed cell lines vs cancer
cell lines. Illumina probe ID and Gene name are listed.
(XLS)
Table S2 Normal Tissue vs Minimally Transformed
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Table S3 Normal Mucosa vs Cancer Cell Lines. Illumina
probe ID and Gene name are listed.
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Table S4 Primary Tumors vs Cancer Cell Lines. Illumina
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Table S8 Genes with differential methylation between
Primary Tumors and Cancer Cell lines in this study and
in Houshdaran et. al., 2010. Gene ID’s are provided.
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